コラム
Zepbound in Japan: Uses, Eligibility and Safety
This guide to Zepbound in Japan covers Japanese treatment criteria, differences from Mounjaro and safety checks. It separates medicine-specific information from the product and prescription checks needed for an individual consultation.
Our clinic does not currently offer prescriptions for this medicine. This article provides general medicine information.
When researching Zepbound (tirzepatide), distinguish the ingredient, the condition being treated, the formulation and the directions for use. This article explains the uses and safety precautions supported by official documentation. It is not intended for self-diagnosis based only on symptoms or for applying someone else’s prescription or an overseas dosage chart to yourself.
Medical reviewer: Masashi Morita, MD
This once-weekly injectable medicine acts on GIP and GLP-1 receptors to regulate appetite and other functions. It contains the same ingredient as Mounjaro, but indications and directions must be distinguished by product. This article explains the medicine to help you understand it. Consult a doctor or pharmacist about individual treatment decisions.
- Ingredient
- Tirzepatide
- Use/patient group
- Obesity
- Before use
- Product name, strength, medical conditions and other medicines
Summary and quick-reference table
This once-weekly injectable medicine acts on GIP and GLP-1 receptors to regulate appetite and other functions. It contains the same ingredient as Mounjaro, but indications and directions must be distinguished by product. This article explains the medicine to help you understand it. Consult a doctor or pharmacist about individual treatment decisions.
| What to check | Key points |
|---|---|
| Ingredient/product | Zepbound (tirzepatide) |
| Scope of the information | Obesity |
| Individual treatment decisions | Review medical conditions and other medicines with a doctor or pharmacist |
| Deciding whether to use it | Discuss contraindications, other medicines, medical conditions and pregnancy with a doctor or pharmacist |
How the medicine works and its ingredients
This once-weekly injectable medicine acts on GIP and GLP-1 receptors to regulate appetite and other functions. It contains the same ingredient as Mounjaro, but indications and directions must be distinguished by product.
Official prescribing information/product documentation (18. Pharmacology).
Approved uses in Japan and the distinction from off-label use
The current Japanese prescribing information includes obesity under specified conditions and moderate or more severe obstructive sleep apnea. Obesity eligibility includes conditions such as hypertension, dyslipidemia or impaired glucose tolerance, together with BMI and associated health problems. Sleep apnea eligibility is also limited by criteria such as BMI. A desire for cosmetic weight loss alone does not make someone eligible.
Official prescribing information/product documentation (4. Indications, 5. Precautions concerning indications).
Check the formulation and directions for use
It is injected subcutaneously once weekly, starting at a low dose and increasing stepwise. Maintenance-dose arrangements differ between obesity and sleep apnea; a doctor adjusts treatment according to side effects and tolerability. Do not repurpose a Mounjaro dose or leftover pen yourself.
Official prescribing information/product documentation (6. Dosage and administration, 7. Precautions concerning dosage and administration).
When treatment may not work well and its limitations
BMI alone cannot establish a self-diagnosis. Comorbidities, the course of diet and exercise therapy, sleep testing and other factors are assessed. Approval for sleep apnea also does not mean that CPAP or other treatment can be stopped yourself.
Official prescribing information/product documentation (5. Precautions concerning indications, 8. Important precautions).
Reviewing the effect and whether to continue treatment
Assess associated health problems, food intake, nutritional status, side effects and the need to continue treatment, as well as weight. Do not predetermine a guaranteed response time or an individual number of kilograms lost.
Official prescribing information/product documentation (8. Important precautions).
Side effects and symptoms requiring medical attention
Besides nausea, vomiting, diarrhea and constipation, watch for acute pancreatitis, biliary disease, hypoglycemia, ileus and serious hypersensitivity reactions. Persistent severe abdominal pain, abdominal distension with vomiting or inability to drink require medical assessment.
Official prescribing information/product documentation (8. Important precautions, 11. Adverse reactions).
When it cannot be used and conditions to disclose
Hypersensitivity to an ingredient, diabetic ketoacidosis and type 1 diabetes are among the contraindications. Disclose past pancreatitis, gastrointestinal disorders, planned surgery or anesthesia, and other diabetes medicines.
Official prescribing information/product documentation (2. Contraindications (patients who must not receive the medicine), 9. Precautions in patients with specific backgrounds).
Other medicines, supplements and everyday precautions
Do not combine it yourself with other tirzepatide or GLP-1 medicines. Concurrent insulin or sulfonylureas require attention to hypoglycemia. Effects on gastric emptying also relate to oral medicine absorption; provide a complete list, including oral contraceptives. Oral contraceptives may be less effective, particularly early after starting treatment or increasing the dose. Discuss contraception with your prescriber or pharmacist rather than changing it yourself.
Official prescribing information/product documentation (10. Interactions, 14. Precautions for administration/use).
Pregnancy and breastfeeding precautions
It must not be administered during pregnancy or possible pregnancy. Consult in advance if you wish to become pregnant. Breastfeeding benefits and risks are assessed individually.
Storage and maintaining product quality
This injectable product is refrigerated and protected from freezing. Follow the actual product instructions for permitted room-temperature conditions and durations; do not use an improperly stored pen. Also check disposal arrangements for used devices with your prescriber.
Official prescribing information/product documentation (Storage and shelf life, 14. Precautions for administration/use).
Differences from related medicines
Mounjaro is a separate product for type 2 diabetes despite containing the same ingredient. Do not transfer Zepbound’s obesity or sleep apnea indications to Mounjaro.
Official prescribing information/product documentation (4. Indications, 6. Dosage and administration, 18. Pharmacology).
What to discuss with a doctor or pharmacist
Clarify associated health problems, the course of diet and exercise therapy, nutritional status and other treatments, as well as BMI. For diabetes, sleep apnea or liver disease, check the respective specialist diagnosis and medicine indication.
This article provides general information about the medicine. Our clinic does not currently offer prescriptions for this medicine. Consult a medical institution that manages the relevant symptoms and indications. If sudden breathing difficulty or altered consciousness occurs, seek emergency care without waiting for an article or an online consultation reply.
Points for safer use
- Confirm the route—oral, topical or injection—and the actual product name and strength.
- Distinguish approval in Japan, off-label use and descriptions in overseas documentation.
- Record benefits and side effects together; do not increase the dose yourself or share medicines.
- Tell a healthcare professional about other medicines, supplements, pregnancy, breastfeeding and medical conditions.
Frequently asked questions
For Zepbound, is it prescribed in the same way as Mounjaro because the ingredient is the same?
Indications, directions and eligibility criteria are product-specific. Even with the same ingredient, approvals and clinical arrangements are not interchangeable. Availability and medical suitability must each be confirmed.
How does Zepbound differ from other medicines or products?
Mounjaro is a separate product for type 2 diabetes despite containing the same ingredient. Do not transfer Zepbound’s obesity or sleep apnea indications to Mounjaro.
Can SWIFT prescribe Zepbound through an online consultation in Japan?
Our clinic does not currently offer prescriptions for this medicine. Discuss its use with the prescribing clinician or an appropriate medical specialty.
Medical reviewer of this article
Dr Masashi Morita
Medical reviewer, Shimbashi Ginza Swift Clinic
- Board-certified specialist and instructor, Japanese Urological Association
- Board-certified specialist, Japan Endocrine Society
- Doctor of Medical Science, Showa University
- Graduate of Showa University School of Medicine
References
- PMDA electronic label (source checked 2026-10-13; primary sources rechecked 2026-10-29)